Market Place
Sourcing Support
Ryvu Reports Q3 2024 Financial Results & Provides Update
07 Nov 2024 //
PR NEWSWIRE
Ryvu Collaborates With Ncage On Next-Gen Adc Platform
29 Oct 2024 //
PR NEWSWIRE
Ryvu Therapeutics Presents Data On RVU120, RVU305 At AACR Symposium
23 Oct 2024 //
PR NEWSWIRE
Ryvu Therapeutics To Present Data At 2024 EORTC-NCI-AACR Symposium
09 Oct 2024 //
PR NEWSWIRE
Ryvu To Present ONCO Prime At RAS-Targeted Drug Summit
23 Sep 2024 //
PR NEWSWIRE
Ryvu Starts Phase II Study Of RVU120 For LR-MDS Anemia
19 Sep 2024 //
PR NEWSWIRE
Ryvu Therapeutics Reports H1 2024 Results And Provides Corporate Update
12 Sep 2024 //
PR NEWSWIRE
Ryvu Presents RVU120 Data At EHA 2024 Congress
14 Jun 2024 //
PR NEWSWIRE
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
15 May 2024 //
PR NEWSWIRE
Ryvu To Present RVU120 Data At EHA 2024 Congress
14 May 2024 //
PR NEWSWIRE
Ryvu Therapeutics Presents Preclinical Data at AACR 2024
10 Apr 2024 //
PR NEWSWIRE
Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
13 Mar 2024 //
PR NEWSWIRE
Ryvu to Present Preclinical Data on RVU120 and Synthetic Lethality Programs
06 Mar 2024 //
PR NEWSWIRE
Ryvu Announces Dosing of First Patient in the RIVER-52 Phase II Study of RVU120
14 Feb 2024 //
PR NEWSWIRE
Ryvu Announces Dosing of the First Patient in RIVER-81 Phase II Study of RVU120
31 Jan 2024 //
PR NEWSWIRE
Ryvu Therapeutics Presents Data on RVU120 at the 2023 ASH Annual Meeting
11 Dec 2023 //
GLOBENEWSWIRE
Ryvu Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
07 Dec 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results
29 Nov 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics to Present Data on RVU120 at the ASH
02 Nov 2023 //
PR NEWSWIRE
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies
23 Oct 2023 //
GLOBENEWSWIRE
Expansion of Clinical Development of RVU120 in LR-MDS
20 Oct 2023 //
PR NEWSWIRE
Ryvu Therapeutics Presents Data on PRMT5 and its Synthetic Lethality Platform
16 Oct 2023 //
PR NEWSWIRE
Ryvu Therapeutics to Present Preclinical Data on PRMT5
04 Oct 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics` Global Licensee Menarini to Expand Development of MEN1703
14 Sep 2023 //
PR NEWSWIRE
Ryvu Reports 2023 Half-Year Financial Results and Provides Corporate Update
13 Sep 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics And Polpharma Partner For RVU120 API Production For Phase II Trials
06 Jul 2023 //
PRESS RELEASE
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120
09 Jun 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics Reports 1Q 2023 FYR and Provides Corporate Update
16 May 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120
11 May 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Ryvu to Participate TheLLS TAP Panel & 12th Annual LifeSci Partnerr Access Event
05 Jan 2023 //
GLOBENEWSWIRE
Ryvu Therapeutics Announces Closing of Equity Offering PLN 250 M
22 Dec 2022 //
GLOBENEWSWIRE
Ryvu Therapeutics Presents Clinical Data of RVU120 and SEL24 (MEN1703) at ASH
11 Dec 2022 //
GLOBENEWSWIRE
BioNTech adds STING to oncology portfolio in €40M Ryvu deal
30 Nov 2022 //
FIERCEBIOTECH
BioNTech and Ryvu Enter into Global Collaboration Small Molecule Candidates
29 Nov 2022 //
GLOBENEWSWIRE
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results
23 Nov 2022 //
GLOBENEWSWIRE
Ryvu Therapeutics Announces Multiple Presentations of Clinical & Data of RVU120
03 Nov 2022 //
GLOBENEWSWIRE
BioNTech and Ryvu Enter into Collaboration to Develop Small Molecule Candidates
30 Oct 2022 //
PRESS RELEASE
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120
26 Oct 2022 //
GLOBENEWSWIRE
Ryvu Therapeutics Announces Poster at the AACR-NCI-EORTC Molecular Targets
12 Oct 2022 //
GLOBENEWSWIRE
EU`s lending arm grants Polish biotech $22M+ in debt financing
17 Aug 2022 //
ENDPTS
EIB to Support Ryvu Therapeutics’ Discovery, R & D of New Cancer Treatments
17 Aug 2022 //
GLOBENEWSWIRE
Ryvu Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to Management Board
26 Jul 2022 //
GLOBENEWSWIRE
Exelixis, Ryvu Sign Excl. Agreement for STING Agonist-Based Cancer Therapies
06 Jul 2022 //
BUSINESSWIRE
Ryvu Therapeutics to Participate in Upcoming Investor Conferences
19 May 2022 //
PRNEWSWIRE
Ryvu Therapeutics Reports First Quarter 2022 Financial Results
18 May 2022 //
PRNEWSWIRE
Ryvu Therapeutics Announces Project Updates at the 2022 ASCO
27 Apr 2022 //
PRNEWSWIRE
Ryvu Therapeutics Announces Presentations at the AACR 2022 Annual Meeting
11 Apr 2022 //
PRNEWSWIRE
Ryvu Tx Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
PRNEWSWIRE
Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer
17 Jan 2022 //
PRNEWSWIRE
Ryvu announces option to license inflammation program exercised by Galapagos NV
13 Dec 2021 //
PRNEWSWIRE
Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society
09 Nov 2021 //
YAHOO
Ryvu Therapeutics& Collab to Present Clinical and Translational Data from RVU120
04 Nov 2021 //
PRNEWSWIRE
Ryvu Therapeutics Reports 2021 Half-Year Financial Results
08 Sep 2021 //
PRNEWSWIRE
Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120)
25 Aug 2021 //
PRNEWSWIRE
Ryvu Presents Positive Phase I Data for RVU120 at Virtual 26th Annual Congress
11 Jun 2021 //
PRNEWSWIRE
Ryvu Presents Positive Phase I Data for RVU120 at Virtual 26th Annual Congress
11 Jun 2021 //
PRNEWSWIRE
Ryvu Presents Positive Phase I Data for RVU120 at Virtual 26th Annual Congress
11 Jun 2021 //
PRNEWSWIRE
Ryvu got full approval to conduct Phase I/II study of RVU120 (SEL120)
28 May 2021 //
PRNEWSWIRE
Ryvu announces participation in the UBS 2021 Global Virtual Conference
17 May 2021 //
PRNEWSWIRE
